IRIDEX CORP (IRIX) - 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended April 4, 2026 (Fiscal Q1 2026). IRIDEX Corporation is an ophthalmic medical technology company developing and commercializing laser systems and consumables for treating glaucoma and retinal diseases. The company operates as a single segment and is classified as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $11.8 million | $11.9 million |
| Gross Profit | $4.7 million | $5.1 million |
| Gross Margin | 40.2% | 42.5% |
| Net Loss | $(0.5) million | $(1.7) million |
| Loss Per Share (Diluted) | $(0.03) | $(0.10) |
| Cash and Equivalents | $4.6 million | $7.2 million (end of Q1 2025) |
| Working Capital | $11.8 million | $12.0 million (as of Jan 3, 2026) |
| Convertible Debt | $3.8 million | $3.7 million |
Material Changes vs. Prior Period
- Revenue: Total revenue decreased slightly by 0.8% ($97,000). This was driven by a 14.5% increase in Glaucoma (Cyclo G6) revenue and a 12.5% increase in "Other" revenue, partially offset by a 12.3% decline in Retina product revenue.
- Profitability: Net loss improved significantly to $0.5 million from $1.7 million in the prior year. This improvement was primarily due to the absence of a $1.3 million loss on the extinguishment of a convertible note payable (Lind Note) recorded in Q1 2025.
- Margins: Gross margin contracted by 230 basis points to 40.2%, attributed to higher manufacturing costs and increased product costs related to recent tariff developments.
- Operating Expenses: General and Administrative (G&A) expenses decreased by 16.0% ($0.3 million) due to lower consulting and legal costs. R&D and Sales & Marketing expenses remained relatively flat.
- Cash Flow: Net cash used in operating activities increased to $1.3 million from $1.1 million, primarily due to a higher operating loss and increased inventory levels ($1.4 million increase in inventory).
Guidance, Outlook, and Risks
- Liquidity: Management believes existing cash ($4.6 million) is sufficient to meet anticipated needs for the next 12 months. The company has an accumulated deficit of approximately $93.0 million.
- Capital Resources: The company has an agreement with Novel Inspirational International Co., Ltd. allowing for the purchase of up to $10 million in additional "Growth Notes" in three installments. No Growth Notes have been issued as of April 4, 2026.
- Risks: Key risks include macroeconomic uncertainty (tariffs, trade wars, geopolitical conflicts), reliance on third-party manufacturers, and the need for future capital raises which could result in dilution. The company notes that customers are extending purchase decision cycles due to economic conditions.
- Unusual Items: The prior year period included a significant one-time loss on debt extinguishment, making the current period's operating performance appear stronger by comparison.
Investor Verification Checklist
- Inventory Build-up: Verify the rationale for the $1.4 million increase in inventory and assess potential obsolescence risks.
- Tariff Impact: Confirm the extent to which recent tariff developments are impacting gross margins and whether cost pass-through to customers is feasible.
- Topcon Concentration: Review the dependency on Topcon Corporation, which accounted for 27% of total revenue and 19% of accounts receivable in Q1 2026.
- Debt Covenants: Review the terms of the $4.0 million convertible note with Novel, including interest payment mechanics (paid in stock) and conversion features.
- Cash Burn Rate: Assess the sustainability of the current cash burn rate ($1.3 million operating cash outflow) against the $4.6 million cash balance.